# reload+after+2024-01-20 12:43:36.731009
address1§1325 Avenue of Americas
address2§28th Floor
city§New York
state§NY
zip§10019
country§United States
phone§201 488 0460
website§https://www.brainstorm-cell.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.
fullTimeEmployees§42
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Chaim  Lebovits', 'age': 52, 'title': 'President & CEO', 'yearBorn': 1971, 'fiscalYear': 2022, 'totalPay': 990419, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Stacy R. Lindborg Ph.D.', 'age': 53, 'title': 'Co-Chief Executive Officer', 'yearBorn': 1970, 'fiscalYear': 2022, 'totalPay': 708393, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Irit  Arbel DSc, Ph.D.', 'age': 63, 'title': 'Co-Founder & Independent Vice Chair of the Board', 'yearBorn': 1960, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Uri  Yablonka', 'age': 46, 'title': 'Executive VP, Chief Business Officer, Secretary & Director', 'yearBorn': 1977, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Alla  Patlis CPA, M.B.A.', 'age': 36, 'title': 'Controller & Interim CFO', 'yearBorn': 1987, 'fiscalYear': 2022, 'totalPay': 80000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Yael  Gothelf', 'title': 'Vice President of Scientific & Regulatory Affairs', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Antal  Pearl-Lendner', 'title': 'VP & Chief Legal Counsel', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Daniel  Offen Ph.D.', 'title': 'Chief Scientific Advisor', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Mary Kay Turner', 'title': 'Senior Vice President of Patient Advocacy & Government Affairs', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. William K. White', 'title': 'Senior VP & Head of Market Access and Pricing', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§9
boardRisk§3
compensationRisk§7
shareHolderRightsRisk§2
overallRisk§4
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§0.212
currency§USD
dateShortInterest§1702598400
forwardEps§-0.47
exchange§NCM
quoteType§EQUITY
shortName§Brainstorm Cell Therapeutics In
longName§Brainstorm Cell Therapeutics Inc.
firstTradeDateEpochUtc§1065533400
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§1aa9d83e-cc55-3d11-a3cf-6388b125b02e
gmtOffSetMilliseconds§-18000000
targetHighPrice§10.0
targetLowPrice§0.5
targetMeanPrice§5.25
targetMedianPrice§5.25
recommendationMean§2.0
recommendationKey§buy
numberOfAnalystOpinions§2
quickRatio§0.235
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
